CMC con­cerns lead to FDA re­jec­tion of Ther­at­e­ch­nolo­gies’ con­cen­trat­ed ver­sion of lipody­s­tro­phy drug for HIV pa­tients

Ther­at­e­ch­nolo­gies was hand­ed a com­plete re­sponse let­ter by the FDA for the more con­cen­trat­ed ver­sion of its mar­ket­ed lipody­s­tro­phy drug for HIV pa­tients, Egrif­ta SV …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER